8-K: Immunic's Phase 3 Multiple Sclerosis Trial Passes Interim Futility Analysis, Trial to Continue Unchanged

Immunic's Phase 3 ENSURE program for relapsing multiple sclerosis treatment, using vidofludimus calcium, has successfully passed its interim futility analysis, allowing the trial to continue as planned.

Summary

• Immunic announced that the interim futility analysis for its Phase 3 ENSURE program, which is evaluating vidofludimus calcium for relapsing multiple sclerosis (RMS), had a positive outcome.
• An independent Data Monitoring Committee (IDMC) reviewed unblinded data and determined that the pre-set futility criteria were not met.
• The IDMC recommended that the trial continue without any changes, including no need for an increase in sample size.
• The ENSURE program consists of two identical trials, ENSURE-1 and ENSURE-2, each enrolling approximately 1,050 patients.
• The primary endpoint of the trials is the time to first relapse, with a follow-up period of up to 72 weeks.
• The completion of ENSURE-1 is expected in the second quarter of 2026, and ENSURE-2 is expected to be completed in the second half of 2026.
• Immunic remains blinded to the data reviewed by the IDMC.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful interim analysis and the IDMC's recommendation to continue the trial without changes. The company's confidence in the drug's potential and the upcoming milestones further contribute to the positive outlook.

Positives

• The positive outcome of the interim analysis validates the initial assumptions for the trial design and powering.
• The trial is proceeding as planned, which reduces uncertainty and potential delays.
• The IDMC's recommendation suggests that the drug is showing promise in the treatment of relapsing multiple sclerosis.
• The company anticipates a top-line readout of the Phase 2 CALLIPER trial in progressive multiple sclerosis in April of next year, which could further validate the drug's potential.
• Vidofludimus calcium has shown an attractive pharmacokinetic, safety and tolerability profile in over 1,800 individuals tested to date.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic, inflation, and geopolitical conflicts.
• There is a risk that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.
• The company's ability to meet business objectives depends on the availability of sufficient financial resources.
• The company faces risks related to drug development, regulatory approval, and competition from other products.

Future Outlook

Immunic expects to complete the ENSURE program in 2026 and anticipates a top-line readout of the Phase 2 CALLIPER trial in progressive multiple sclerosis in April of next year. The company is confident in vidofludimus calcium's potential to transform the oral MS market and believes the phase 3 program provides a clear path towards potential regulatory approval in RMS.

Management Comments

• Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic, stated that the IDMC's favorable recommendations corroborate the initial assumptions for the design, powering, and relapse rate of the trials.
• Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, expressed excitement about the positive outcome of the interim analysis, calling it a critical milestone for the program.
• Daniel Vitt also stated that they are confident in vidofludimus calcium's potential to transform the oral MS market.

Industry Context

This announcement is significant in the context of the competitive landscape for multiple sclerosis treatments, particularly oral therapies. The successful interim analysis positions Immunic as a potential key player in the market, especially if the Phase 2 CALLIPER trial in progressive MS also yields positive results.

Comparison to Industry Standards

• The ENSURE program's design, with two identical trials each enrolling approximately 1,050 patients, is consistent with large-scale Phase 3 trials in multiple sclerosis.
• The primary endpoint of time to first relapse is a standard measure in MS clinical trials.
• The use of an independent Data Monitoring Committee (IDMC) for interim analysis is a common practice to ensure trial integrity and patient safety.
• Other companies developing oral MS treatments include Novartis (Mayzent), Biogen (Tecfidera), and Sanofi (Aubagio).
• The success of Immunic's trial will be measured against the efficacy and safety profiles of these existing treatments.

Stakeholder Impact

• Shareholders are likely to react positively to the news of the successful interim analysis.
• Patients with relapsing multiple sclerosis may benefit from the potential availability of a new treatment option.
• Employees of Immunic may be motivated by the progress of the clinical program.
• The positive results may attract potential partners and investors.

Next Steps

• The ENSURE program will continue as planned, with completion expected in 2026.
• The company will release top-line results from the Phase 2 CALLIPER trial in progressive multiple sclerosis in April of next year.
• Immunic will continue to monitor the progress of the trials and provide updates as appropriate.

Key Dates

Keywords

vidofludimus calcium, multiple sclerosis, relapsing multiple sclerosis, ENSURE program, IMU-838, clinical trial, interim analysis, IDMC, Nurr1, autoimmune diseases, biotechnology